Vertero Biotech

Vertero Biotech is a pre-clinical stage biotechnology company focused on transforming the delivery of biologics from injections to oral capsules. The company's core technology, developed at MIT and Brigham and Women's Hospital, involves ingestible devices that can autonomously orient themselves and inject medication into the stomach lining. This platform, often referred to as the Self-Orienting Millimeter-Scale Actuator (SOMA), is designed to deliver a wide range of macromolecules, including insulin, GLP-1 receptor agonists, and monoclonal antibodies. By enabling oral administration of these complex therapies, Vertero aims to significantly improve patient adherence and quality of life for those with chronic diseases. The company maintains a significant strategic partnership with Novo Nordisk to advance its oral delivery solutions.